Cohance Lifesciences Investment Push for ADC Growth

Cohance Lifesciences is stepping up its focus on the high-potential Antibody-Drug Conjugate (ADC) segment with two proposed strategic transactions. The company plans an additional $13 million investment in NJ Bio and a $5 million controlling investment in Aruka Bio, taking the total proposed investment to $18 million. Importantly, both transactions will be funded through internal accruals, indicating that Cohance intends to deploy its existing financial resources toward expanding its advanced biologics capabilities. The move could strengthen Cohance’s position in ADC development and manufacturing, a rapidly evolving area of targeted cancer therapies. Meanwhile, Cohance shares were trading at ₹458.85 at 1:46 PM IST today, down 0.43%, with the stock hovering near the day’s low and approximately 0.5% lower during the session. With these investments, Cohance appears to be positioning itself for long-term opportunities in next-generation oncology therapies. COHANCE LIFESCIENCES — FUNDAMENTAL SNAPSHOT 52W High/Low: ₹1,039 / ₹267 P/E: 165.3× — significantly above the sector multiple of ~63× P/B: 4.49× ROE: 4.58% — relatively weak ROCE: 5.39% — moderate/low Disclaimer: Investments in securities are subject to market risk. This is for informational purposes only. Investors must verify information before investing and consider their financial position & risk profile.